10-K: InspireMD Reports Positive C-GUARDIANS Trial Results, Eyes FDA Approval in 2025

InspireMD's C-GUARDIANS trial demonstrates positive one-year follow-up results, supporting a PMA submission for potential FDA approval of the CGuard Prime carotid stent system in the first half of 2025.

Summary

• InspireMD, Inc. is a medical device company focused on developing and commercializing products for treating carotid artery and other vascular diseases, featuring its proprietary CGuard stent platform.
• The CGuard EPS received CE mark recertification in January 2024 under the EU's Medical Device Regulation regulatory framework.
• The C-GUARDIANS trial, evaluating the CGuard Carotid Stent System, completed enrollment in June 2023 with 316 patients across 24 sites in the U.S. and Europe.
• Positive 30-day follow-up results from the C-GUARDIANS trial showed a DSMI rate of 0.95% in patients with carotid artery stenosis at high risk for carotid endarterectomy.
• One-year follow-up results from the C-GUARDIANS trial demonstrated a 30-day DSMI and ipsilateral stroke rate of 1.95%.
• A premarket approval (PMA) submission was made in September 2024, targeting potential FDA approval of the CGuard Prime carotid stent system in the first half of 2025.
• The FDA approved the company's IDE to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures in October 2024.
• The company estimates the addressable market for CGuard Carotid Stent System and SwitchGuard NPS is approximately $1.3 billion, with a total available market of approximately $9.3 billion.
• In October 2024, InspireMD established its global headquarters in Miami, Florida, to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system.
• The company reported a net loss of $32.0 million for the fiscal year ended December 31, 2024, and had an accumulated deficit of $254 million as of the same date.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive clinical trial results and potential FDA approval are counterbalanced by ongoing losses and the need for additional capital.

Positives

• Positive clinical trial results from the C-GUARDIANS trial support the potential FDA approval of the CGuard Prime carotid stent system.
• Expansion of coverage for both CAS and TCAR to include both asymptomatic and standard risk patients, significantly expanding and supporting the future growth of the U.S. CAS addressable market.
• FDA approval of IDE for CGUARDIANS II study to evaluate CGuard Prime 80cm Carotid Stent System during TCAR procedures.
• Estimated addressable market for CGuard Carotid Stent System and SwitchGuard NPS is approximately $1.3 billion, with a total available market of approximately $9.3 billion.
• Establishment of global headquarters in Miami, Florida, to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system.

Negatives

• The company reported a net loss of $32.0 million for the fiscal year ended December 31, 2024, and had an accumulated deficit of $254 million as of the same date.
• The company has a history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives, and substantial doubt regarding our ability to continue as a going concern.

Risks

• The company has a history of net losses and may experience future losses.
• The company will need to raise additional capital to meet business requirements in the future, and such capital raising may be costly or difficult to obtain and could dilute stockholders ownership interests.
• The company may become subject to claims by much larger and better capitalized competitors enforcing their intellectual property rights against the company or seeking to invalidate the company's intellectual property or the company's rights thereto.
• Completing clinical trials for CGuard Carotid Stent System and SwitchGuard NPS in the United States require meeting a number of regulatory requirements and must be conducted in compliance with the FDA's IDE regulations.
• Clinical trials necessary to support a pre-market approval application will be lengthy and expensive and will require the enrollment of a large number of patients, and suitable patients may be difficult to identify and recruit.
• The results of the company's clinical trials may be insufficient to obtain regulatory approval for the company's products.
• The company's products may in the future be subject to product notifications, recalls, or voluntary market withdrawals that could harm the company's reputation, business and financial results.
• The company may be subject, directly or indirectly, to applicable U.S. federal and state anti-kickback, false claims laws, physician payment transparency laws, fraud and abuse laws or similar healthcare and security laws and regulations, which could expose the company to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
• The company may be exposed to product liability claims and insurance may not be sufficient to cover these claims.
• Even if one or more of the company's products are approved by the FDA, the company may fail to obtain an adequate level of reimbursement for the company's products by third party payors, such that there may be no commercially viable markets for the company's products or the markets may be much smaller than expected.
• In the United States and European Union, the company's business could be significantly and adversely affected by healthcare reform initiatives and/or other legislation or judicial interpretations of existing or future healthcare laws and/or regulations.
• If the company is unable to obtain and maintain intellectual property protection covering the company's products, others may be able to make, use or sell the company's products, which would adversely affect the company's revenue.
• The company is an international business, and the company is exposed to various global and local risks that could have a material adverse effect on the company's financial condition and results of operations venue.
• The company's business, operating results and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk.
• There are inherent limitations in all control systems, and misstatements due to error or fraud may occur and not be detected.
• The company anticipates being subject to fluctuations in currency exchange rates because the company expects a substantial portion of the company's revenues will be generated in Euros and U.S. dollars, while a significant portion of the company's expenses will be incurred in New Israeli Shekels.
• If there are significant shifts in the political, economic and military conditions in Israel and its neighbours, it could have a material adverse effect on the company's business relationships and profitability.
• It may be difficult for investors in the United States to enforce any judgments obtained against the company or some of the company's directors or officers.
• The market prices of the company's common stock and the company's publicly traded warrants are subject to fluctuation and have been and may continue to be volatile, which could result in substantial losses for investors; and
• The company's common stock could be delisted from the Nasdaq Stock Market if the company fail to meet its continued listing requirements, including requirements with respect to the market value of publicly-held-shares, market value of listed shares, minimum bid price per share, and minimum stockholders equity, among others, and requirements relating to board and committee independence.

Future Outlook

The company anticipates potential FDA approval of the CGuard Prime carotid stent system in the first half of 2025 and plans to continue investing in new indications, products, and manufacturing enhancements.

Industry Context

The company competes in the carotid artery stenting market with larger companies like Abbott, Boston Scientific, Medtronic, Cordis, and Terumo, but believes the European market is more fragmented, allowing smaller competitors to gain market share.

Comparison to Industry Standards

• The performance goal for the C-GUARDIANS trial was considered met if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is < 11.6% and the p-value is less than 0.025.
• The 30-day death or stroke rate of 0.75% in the PARADIGM-500 study is comparable to industry standards.
• The 12-month ISR rate in the PARADIGM-500 study is lower than those reported in the literature of first-generation stents (Naylor R, et al. European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2023).

Related Party Transactions

• A consulting company whose founder and chief executive officer is one of our board members provided certain marketing services in the amount of $ 788 during the year ended December 31, 2023.
• The board approved the companys entry into a consultancy agreement with a member of the immediate family of the Companys chief executive officer for certain administrative projects in connection with the Companys expansion to the U.S. until a full-time Company employee is retained in such capacity.
• During 2023, certain non-employee directors elected to receive all or a portion of their cash retainer amount in shares of the Companys common stock under the 2021 Equity Incentive Plan.

Stakeholder Impact

• Positive clinical trial results and potential FDA approval could benefit patients with carotid artery disease.
• Expansion into the U.S. market could create new job opportunities.
• Continued losses and the need for additional capital could impact shareholder value.

Next Steps

• Pursue potential FDA approval of the CGuard Prime carotid stent system in the first half of 2025.
• Initiate the CGUARDIANS II pivotal study of the CGuard Prime 80cm Carotid Stent System during TCAR procedures.
• Continue to invest in new indications, products, and manufacturing enhancements for CGuard.
• Seek strategic partners for a potential launch of CGuard EPS in Japan and other Asian countries.

Key Dates